Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)

Posted by Matt Breese on Oct 30, 2020

Find me on:

According to our recent payer coverage analysis for hepatocellular carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hepatocellular carcinoma treatments shows that under the pharmacy benefit, about 59% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Hepatocellular Carcinoma-4Q2020Data snapshot as of Q4 2020

Trends: In May 2020, the FDA expanded the indication for Roche's Tecentriq (atezolizumab) in combination with bevacizumab for the treatment of people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.   

To read the full Reality Check on Hepatocellular Carcinoma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing